About this Research Topic
Prostate cancer (PCa) is one of the most frequent global malignancies, accounting for the second most common malignancy in men. The International Society of Urological Pathology (ISUP) proposed a grading scale based on the histology of PCa which predicts the aggressiveness of the tumor. Based on this grading, PCa can be classified into low grade, non-significant PCa (ISUP 1) and clinically significant PCa (ISUP ≥2). In practice, active surveillance is an option for ISUP 1 PCa (and in some centers even for ISUP 2). Even if PI-RADS criteria were designed to diagnose only clinically significant PCa (ISUP ≥2), the rate of low grade PCa diagnosis is increased, arriving in some cases to 90% of all biopsy specimens analyzed. It is now well established that prostate MRI can rule out clinically significant prostate cancer and therefore lower the number of unnecessary prostate biopsies.
The goal of this Research Topic is to present improvements which can be made to the protocol of prostate MRI and to the PI-RADS criteria to reduce the number of biopsies made for patients with no malignant prostate pathology or with ISUP 1, i.e. with non-significant prostate cancer. Prostate biopsy can have some serious adverse effects such as hematuria, rectal bleeding, and infectious complications. Therefore, it is important to avoid prostate biopsy if no significant PCa is suspected. Inconsistence of reporting between radiologists, difference in quality of images and a long learning curve are all drawbacks which will lead to a decrease of accuracy of MRI and to an increase of prostate biopsies. Even if there is evidence that MRI is helpful in estimating the agressivness of PCa, there is yet no consensus on this topic and therefore a category of lesions which can be followed only based on their MRI aspect has not yet been defined.
We would like to address specific questions to through this topic:
-Is there a role for radiomics in the differentiation between benign prostate pathology, non-significant prostate cancer and significant prostate cancer?
-Can the protocol of prostate MRI be improved by adding new sequences?
-Can biparametric prostate MRI replace multiparametric MRI in the evaluation of patients with elevated blood PSA?
We welcome Original Research, Reviews, Systematic Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
The goal of this Research Topic is to present improvements which can be made to the protocol of prostate MRI and to the PI-RADS criteria to reduce the number of biopsies made for patients with no malignant prostate pathology or with ISUP 1, i.e. with non-significant prostate cancer. Prostate biopsy can have some serious adverse effects such as hematuria, rectal bleeding, and infectious complications. Therefore, it is important to avoid prostate biopsy if no significant PCa is suspected. Inconsistence of reporting between radiologists, difference in quality of images and a long learning curve are all drawbacks which will lead to a decrease of accuracy of MRI and to an increase of prostate biopsies. Even if there is evidence that MRI is helpful in estimating the agressivness of PCa, there is yet no consensus on this topic and therefore a category of lesions which can be followed only based on their MRI aspect has not yet been defined.
We would like to address specific questions to through this topic:
-Is there a role for radiomics in the differentiation between benign prostate pathology, non-significant prostate cancer and significant prostate cancer?
-Can the protocol of prostate MRI be improved by adding new sequences?
-Can biparametric prostate MRI replace multiparametric MRI in the evaluation of patients with elevated blood PSA?
We welcome Original Research, Reviews, Systematic Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: Prostate cancer, Prostate MRI, PI-RADS
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
